The drug risedronate is said to significantly reduce the risk of hip fracture in women with osteoporosis.
Experts studied the drug risedronate and its function in reducing hip fracture incidence. The outcome reflected that the drug reduces the risk for hip fracture in elderly women with low femoral (relating to the femur) neck bone mineral density by nearly 40 percent over a span of three years.
It is a known fact that older adults are commonly affected by osteoporosis. The disorder causes bones to become porous, brittle and fragile. Osteoporosis is especially prevalent in postmenopausal women. The disorder may result in hip fractures and may ultimately affect the quality of the patient’s life. About 2/3 of the patients who experience a hip fracture rely on assistance on a quotidian basis.
Source: Doctor’s Guide